CLINICAL TRIALS PROFILE FOR OZEMPIC
✉ Email this page to a colleague
All Clinical Trials for Ozempic
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03596450 ↗ | Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial | Active, not recruiting | Novo Nordisk A/S | Phase 4 | 2018-07-13 | The main purpose of this study is to compare the effects of semaglutide (Ozempic®) with the effects of other treatments for type 2 diabetes in a normal practice setting. The participant will be assigned by chance (like flipping a coin) to one of the following treatment groups: Group 1: semaglutide (Ozempic®) (by injection into skin) Group 2: standard of care antidiabetic medication (oral or injectable). The participant has an equal chance of being in either of the treatment groups. Neither the participant nor the study doctor or study staff will be able to pick which group the participant is in, but the participant will know which study drug the participant has been assigned to. The study doctor will provide the participant with a prescription for the study diabetes medication based on the treatment group the participant is assigned. The participation will last about 2 years. |
| NCT03724981 ↗ | A Study Comparing the Dulaglutide Pen and the Semaglutide Pen | Completed | Eli Lilly and Company | Phase 4 | 2018-10-18 | In this study participants will try out two different types of drug injection pens (dulaglutide and semaglutide) on a practice pad and decide which device they prefer. No study drug will be administered. |
| NCT03899402 ↗ | Triple Therapy in T1DM | Recruiting | University of Glasgow | Phase 2/Phase 3 | 2019-05-01 | To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment. |
| NCT03899402 ↗ | Triple Therapy in T1DM | Recruiting | State University of New York at Buffalo | Phase 2/Phase 3 | 2019-05-01 | To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment. |
| NCT04019197 ↗ | Effects of Semaglutide in HIV-Associated Lipohypertrophy | Recruiting | Medical University of South Carolina | Phase 2 | 2019-05-16 | This is a randomized, double-blinded, placebo-controlled trial designed to assess the effect of the GLP-1 receptor agonist, semaglutide, on visceral and ectopic fat, insulin resistance, inflammation markers, and the downstream effect of cardiovascular risk in people with HIV. The primary endpoints will be visceral and ectopic fat changes over the study period. The secondary endpoints will include changes in markers of inflammation, immune activation, gut integrity, and cardiovascular disease risk assessment. |
| NCT04019197 ↗ | Effects of Semaglutide in HIV-Associated Lipohypertrophy | Recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | 2019-05-16 | This is a randomized, double-blinded, placebo-controlled trial designed to assess the effect of the GLP-1 receptor agonist, semaglutide, on visceral and ectopic fat, insulin resistance, inflammation markers, and the downstream effect of cardiovascular risk in people with HIV. The primary endpoints will be visceral and ectopic fat changes over the study period. The secondary endpoints will include changes in markers of inflammation, immune activation, gut integrity, and cardiovascular disease risk assessment. |
| NCT04019197 ↗ | Effects of Semaglutide in HIV-Associated Lipohypertrophy | Recruiting | Case Western Reserve University | Phase 2 | 2019-05-16 | This is a randomized, double-blinded, placebo-controlled trial designed to assess the effect of the GLP-1 receptor agonist, semaglutide, on visceral and ectopic fat, insulin resistance, inflammation markers, and the downstream effect of cardiovascular risk in people with HIV. The primary endpoints will be visceral and ectopic fat changes over the study period. The secondary endpoints will include changes in markers of inflammation, immune activation, gut integrity, and cardiovascular disease risk assessment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Ozempic
Condition Name
Clinical Trial Locations for Ozempic
Trials by Country
Clinical Trial Progress for Ozempic
Clinical Trial Phase
Clinical Trial Sponsors for Ozempic
Sponsor Name
